Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12564571 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL18709165 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL25984102 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL18858339 | 0.91 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL17949819 | 0.90 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL10092579 | 0.89 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL26477155 | 0.88 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL4890742 | 0.87 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL24591323 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA | |
| SCHEMBL27489823 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC15A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636411-B2 | Large scale process for preparing poly (glutamyl-glutamate) conjugates | NITTO DENKO CORPORATION (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20160074524-A1 | A LARGE SCALE PROCESS FOR PREPARING POLY (GLUTAMYL-GLUTAMATE) CONJUGATES | NITTO DENKO CORPORATION (JP) | 2016-03-17 | — | — | US | disclosed |
| US-20090326219-A1 | PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2009-12-31 | — | — | US | disclosed |
| US-20090326219-A1 | PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2009-12-31 | — | — | US | disclosed |
| EP-1758948-B1 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KK (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-03-26 | — | — | US | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
| US-4154937-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4128653-A | Reduction of blood pressure with carboxyalkylacyl-pipecolic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4086338-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4052511-A | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074524-A1 | A LARGE SCALE PROCESS FOR PREPARING POLY (GLUTAMYL-GLUTAMATE) CONJUGATES | GLUL, QPCT, GGCT | ALDH1A1 1602/4885MAPK1 4531/4885L3MBTL1 1941/4885 |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | ALDH1A1 2196/4885MAPK1 1269/4885L3MBTL1 3874/4885 |
| US-20090326219-A1 | PROCESS FOR MANUFACTURING EXTREMELY PURE BENZAZEPINE DERIVATIVES | BBOX1, ADRM1, DRD2 | ALDH1A1 1199/4885MAPK1 1104/4885L3MBTL1 2945/4885 |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | ALDH1A1 4098/4885MAPK1 3153/4885L3MBTL1 806/4885 |
| US-20090082368-A1 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | NGF, BDNF, NTRK2 | ALDH1A1 2086/4885MAPK1 3417/4885L3MBTL1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.